Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Invivyd often means wading through hundreds of pages to locate one cash-runway table or a single trial update. If you have ever searched “Invivyd SEC filings explained simply” or wondered which variant data moved the share price, you know the challenge.
Stock Titan solves that problem. Our AI reads every Invivyd annual report 10-K simplified, parses each Invivyd quarterly earnings report 10-Q filing, and flags fresh Invivyd 8-K material events explained within minutes of hitting EDGAR. Interactive summaries highlight R&D spend, dilution risk, and regulatory milestones, while side-by-side charts let you compare pipeline disclosures over time.
Need real-time trade intel? Form 4 alerts surface Invivyd executive stock transactions Form 4, giving you immediate insight into insider sentiment. Our dashboard also groups every Invivyd proxy statement executive compensation section, so you can evaluate incentives driving decision-making.
- AI-powered summaries translate technical immunology terms into plain English
- Instant notifications for Invivyd Form 4 insider transactions real-time
- Side-by-side “redline” view of successive reports for quick change detection
Whether you type “Invivyd earnings report filing analysis,” “understanding Invivyd SEC documents with AI,” or “Invivyd insider trading Form 4 transactions,” this page delivers the answers—and the filings—without the usual time sink.
Invivyd, Inc. entered into an underwriting agreement for an underwritten public offering of 44,000,000 shares of common stock and pre-funded warrants to purchase 6,000,000 shares. The shares were priced at $2.50 each and the pre-funded warrants at $2.4999, with an option for underwriters to buy up to an additional 7,500,000 shares at the same price. The company reports net proceeds of approximately $117.2 million after fees, and the offering closed on November 19, 2025.
Invivyd plans to use the proceeds, together with existing cash, to prepare commercially for the potential launch of VYD2311, continue research and development for programs such as RSV and measles, advance its SPEAR Study Group work on Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and general corporate purposes. The pre-funded warrants are exercisable immediately, have no expiration, allow cash or cashless exercise, and include beneficial ownership limits generally starting at 4.99% or 9.99%, adjustable up to 19.99% with at least 61 days’ prior notice.
Invivyd, Inc. is conducting a primary offering of 44,000,000 shares of common stock and pre-funded warrants to purchase up to 6,000,000 shares at a public offering price of $2.50 per share and $2.4999 per pre-funded warrant, for gross proceeds of $124,999,400. After underwriting discounts and estimated expenses, Invivyd expects net proceeds of about $117.2 million, or $134.8 million if underwriters fully exercise their option to buy an additional 7,500,000 shares. The company plans to use the cash to prepare for the potential launch of its COVID-19 antibody VYD2311, advance pipeline programs such as RSV and measles, support Long COVID research via the SPEAR Study Group, and for working capital and general corporate purposes. The transaction will dilute existing holders, with pro forma net tangible book value rising from $0.52 to about $0.84 per share, implying $1.66 per-share dilution to new investors paying the offering price.
Invivyd, Inc. is conducting an underwritten public offering of its common stock on the Nasdaq Global Market under an effective shelf registration statement. This primary equity raise is expected to provide additional capital for the company’s COVID-19 antibody franchise and broader pipeline.
Invivyd is a biopharmaceutical company focused on monoclonal antibodies that protect against serious viral diseases, starting with SARS‑CoV‑2. Its first authorized product, PEMGARDA (pemivibart), has U.S. emergency use authorization for pre‑exposure COVID‑19 prevention in certain immunocompromised patients. The company is also advancing VYD2311 through its REVOLUTION clinical program, including planned Phase 3 trials, and plans to use offering proceeds alongside existing cash to support potential commercialization of VYD2311, additional R&D such as RSV and measles programs, Long COVID research via the SPEAR Study Group, and general corporate purposes.
Invivyd, Inc. reported Q3 2025 results showing higher revenue and sharply lower operating expenses, alongside a going concern warning. Product revenue reached $13.1 million, up from $9.3 million a year ago. The net loss narrowed to $10.5 million from $60.7 million, driven by a large decline in research and development expense ($8.0 million vs. $57.9 million). Cash and cash equivalents were $84.97 million, up from $69.35 million at year-end.
The company strengthened liquidity through equity financings, including an underwritten public offering and at‑the‑market sales, bringing in $58.45 million of net cash in the nine months ended September 30, 2025. Stockholders’ equity improved to $93.07 million from $67.54 million. Management disclosed “substantial doubt” about the ability to continue as a going concern without additional funding.
Operationally, PEMGARDA remains authorized under EUA. The FDA cleared the IND for VYD2311 in October 2025, with Phase 3 trials (DECLARATION and LIBERTY) expected to begin around year‑end 2025 and top‑line data anticipated mid‑2026. As of October 30, 2025, shares outstanding were 233,122,834.
Invivyd, Inc. (IVVD) filed an 8-K reporting Q3 2025 updates. The company furnished a press release announcing financial results for the quarter ended September 30, 2025 as Exhibit 99.1 under Item 2.02. This information is furnished and not deemed filed under Section 18 of the Exchange Act.
Invivyd also posted an updated corporate presentation on November 6, 2025, filed as Exhibit 99.2 and available on its website. The filing lists these materials and related exhibit identifiers.
Invivyd (IVVD)Exhibit 99.1
Invivyd, Inc. filed a shelf registration on Form S-3 that describes its authorized monoclonal antibody PEMGARDA (pemivibart) for pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years and older weighing at least 40 kg who are moderately-to-severely immunocompromised and unlikely to mount an adequate vaccine response. The prospectus highlights the company’s investigational mAb VYD2311, which began dosing in a Phase 1/2 trial in September 2024 and showed positive full Phase 1/2 safety and pharmacokinetics data in June 2025. In August 2025 the company reported FDA advice supporting a compact Phase 2/3 trial that could support a BLA submission, subject to agreement on safety database size and protocol review. The filing reports ongoing variant neutralization updates in Jan 2025, Mar 2025, and Aug 2025, includes pro forma net tangible book value of approximately $169.1 million or $0.58 per share as of June 30, 2025, and notes pre-funded warrants exercisable for 21,342,442 shares and other offering mechanics.
Paul Bolno, a director of Invivyd, Inc. (IVVD), was granted a stock option on 09/22/2025 to buy 100,000 shares of common stock at an exercise price of $1.22 per share. The option expires on 09/21/2035. The grant vests over three years: one-third vests on the first anniversary of the grant and the remainder vests in equal monthly installments (1/36th) thereafter, subject to continuous service through each vesting date. Following the grant, the reporting person beneficially owns 100,000 option shares, held directly. The Form 4 was filed with a signature dated 09/24/2025 by an attorney-in-fact.
Invivyd Form 3 filed for Paul Bolno reports that Paul Bolno, identified as a director of Invivyd, Inc. (IVVD), has filed an initial Section 16 statement and discloses no securities beneficially owned as of the event date. The form lists the reporting person's address as c/o Invivyd, Inc., 209 Church Street, New Haven, CT. The filing is signed by an attorney-in-fact for Mr. Bolno and includes a Power of Attorney reference as an exhibit.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
